G

ood morning, everyone. Damian Garde here, filling in for Ed Silverman on a day that marks the belated but not unwelcome return of warm weather here on Pharmalot’s satellite campus. Please find, as always, a few headlines from around the industry to get your day started. If you see something interesting out there, please do let us know. We’ll do the same.

There could be a nativist row brewing in the boardroom of Teva. According to Israeli news outlet Calcalist, the company’s CEO search committee has picked a foreigner as the leading candidate to replace departed chief Erez Vigodman. But some members of Teva’s board are demanding that an Israeli get the job, Calcalist says, which could set the stage for a fight in a boardroom once memorably described as “a nuthouse.”

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.